287 related articles for article (PubMed ID: 27903753)
1. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
2. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
[TBL] [Abstract][Full Text] [Related]
4. Growth Factor Independence 1B-Mediated Transcriptional Repression and Lineage Allocation Require Lysine-Specific Demethylase 1-Dependent Recruitment of the BHC Complex.
McClellan D; Casey MJ; Bareyan D; Lucente H; Ours C; Velinder M; Singer J; Lone MD; Sun W; Coria Y; Mason CC; Engel ME
Mol Cell Biol; 2019 Jul; 39(13):. PubMed ID: 30988160
[TBL] [Abstract][Full Text] [Related]
5. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
6. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
7. Differential transcriptional regulation of meis1 by Gfi1b and its co-factors LSD1 and CoREST.
Chowdhury AH; Ramroop JR; Upadhyay G; Sengupta A; Andrzejczyk A; Saleque S
PLoS One; 2013; 8(1):e53666. PubMed ID: 23308270
[TBL] [Abstract][Full Text] [Related]
8. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
9. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
[TBL] [Abstract][Full Text] [Related]
10. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice.
Matsuda S; Baba R; Oki H; Morimoto S; Toyofuku M; Igaki S; Kamada Y; Iwasaki S; Matsumiya K; Hibino R; Kamada H; Hirakawa T; Iwatani M; Tsuchida K; Hara R; Ito M; Kimura H
Neuropsychopharmacology; 2019 Jul; 44(8):1505-1512. PubMed ID: 30580376
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
12. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
[TBL] [Abstract][Full Text] [Related]
14. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
16. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation.
Sprüssel A; Schulte JH; Weber S; Necke M; Händschke K; Thor T; Pajtler KW; Schramm A; König K; Diehl L; Mestdagh P; Vandesompele J; Speleman F; Jastrow H; Heukamp LC; Schüle R; Dührsen U; Buettner R; Eggert A; Göthert JR
Leukemia; 2012 Sep; 26(9):2039-51. PubMed ID: 22699452
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
18. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
19. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
20. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
